Global DNA methylation changes in treated and untreated MS patients measured over time
Multiple sclerosis (MS) is an autoimmune, neurological disease. We investigated genome-wide DNA methylation profiles of CD4+ and CD8+ T cells from MS patients and healthy controls at baseline and a follow-up visit. Patients were all treatment-naïve at baseline, and either on treatment or remained un...
Gespeichert in:
| Veröffentlicht in: | Journal of neuroimmunology 2022-03, Vol.364, p.577808-577808, Article 577808 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 577808 |
|---|---|
| container_issue | |
| container_start_page | 577808 |
| container_title | Journal of neuroimmunology |
| container_volume | 364 |
| creator | Brorson, I.S. Eriksson, A.M. Høgestøl, E. Leikfoss, I.S. Harbo, H.F. Berge, T. Vitelli, V. Bos, S.D. |
| description | Multiple sclerosis (MS) is an autoimmune, neurological disease. We investigated genome-wide DNA methylation profiles of CD4+ and CD8+ T cells from MS patients and healthy controls at baseline and a follow-up visit. Patients were all treatment-naïve at baseline, and either on treatment or remained untreated at the follow-up visit. MS patients show more changes in their T cell DNA methylation profiles as compared to healthy controls over time, with the most pronounced differences observed in the untreated MS patients. These findings underline the potential of DNA methylation as biomarkers in MS.
[Display omitted]
•Genome-wide DNA methylation profiles were obtained from MS patients and healthy controls at baseline and one follow-up visit.•MS patients were treatment-naïve at baseline, and untreated or on treatment with immunomodulatory drugs at follow-up.•MS patients show more changes in their DNA methylation profiles compared to healthy controls over time.•Untreated MS patients show more differential DNA methylation at follow-up as compared to treated MS patients .•There is an abundance of hypermethylated DMPs in CD8+ T cells from treated and untreated MS patients at the follow-up visit. |
| doi_str_mv | 10.1016/j.jneuroim.2022.577808 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_crist</sourceid><recordid>TN_cdi_cristin_nora_10852_96029</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165572822000030</els_id><sourcerecordid>2624201466</sourcerecordid><originalsourceid>FETCH-LOGICAL-c440t-f1cccf579eddf91a015ca53279bb8bd40d8bc0c44f7d5f32c0d55346f6e06223</originalsourceid><addsrcrecordid>eNqFkMtOxCAUhonR6Hh5BWXppiPQQtudxnviZaFxSyicKpMWRqAm8_ZixnHrikC-_z-HD6FjSuaUUHG2mC8cTMHbcc4IY3Ne1w1pttCMNjUrmorRbTTLIC94zZo9tB_jghDKy6rdRXslJ21ZCzZDb7eD79SAr54u8AjpYzWoZL3D-kO5d4jYOpwCqAQGK2fw5Da3xxe8zCi4FHNQxSnkR_8FASc7wiHa6dUQ4ej3PECvN9evl3fFw_Pt_eXFQ6GriqSip1rrntctGNO3VOUFteIlq9uuazpTEdN0mmS2rw3vS6aJ4fkLohdABGPlATpZ1-pgY7JOOh-UpKThTLaCsDYTp2tiGfznBDHJ0UYNw6Ac-ClKJljFCK2EyKjYlPkYA_RyGeyowioXyh_pciE30uWPdLmWnoPHvzOmbgTzF9tYzsD5GoCs4stCkFFncxqMDaCTNN7-N-Mb65SVsA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2624201466</pqid></control><display><type>article</type><title>Global DNA methylation changes in treated and untreated MS patients measured over time</title><source>MEDLINE</source><source>NORA - Norwegian Open Research Archives</source><source>Elsevier ScienceDirect Journals</source><creator>Brorson, I.S. ; Eriksson, A.M. ; Høgestøl, E. ; Leikfoss, I.S. ; Harbo, H.F. ; Berge, T. ; Vitelli, V. ; Bos, S.D.</creator><creatorcontrib>Brorson, I.S. ; Eriksson, A.M. ; Høgestøl, E. ; Leikfoss, I.S. ; Harbo, H.F. ; Berge, T. ; Vitelli, V. ; Bos, S.D.</creatorcontrib><description>Multiple sclerosis (MS) is an autoimmune, neurological disease. We investigated genome-wide DNA methylation profiles of CD4+ and CD8+ T cells from MS patients and healthy controls at baseline and a follow-up visit. Patients were all treatment-naïve at baseline, and either on treatment or remained untreated at the follow-up visit. MS patients show more changes in their T cell DNA methylation profiles as compared to healthy controls over time, with the most pronounced differences observed in the untreated MS patients. These findings underline the potential of DNA methylation as biomarkers in MS.
[Display omitted]
•Genome-wide DNA methylation profiles were obtained from MS patients and healthy controls at baseline and one follow-up visit.•MS patients were treatment-naïve at baseline, and untreated or on treatment with immunomodulatory drugs at follow-up.•MS patients show more changes in their DNA methylation profiles compared to healthy controls over time.•Untreated MS patients show more differential DNA methylation at follow-up as compared to treated MS patients .•There is an abundance of hypermethylated DMPs in CD8+ T cells from treated and untreated MS patients at the follow-up visit.</description><identifier>ISSN: 0165-5728</identifier><identifier>EISSN: 1872-8421</identifier><identifier>DOI: 10.1016/j.jneuroim.2022.577808</identifier><identifier>PMID: 35093762</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adult ; CD4+ T cells ; CD4-Positive T-Lymphocytes - immunology ; CD8+ T cells ; CD8-Positive T-Lymphocytes - immunology ; Differentially methylated position ; DNA methylation ; DNA Methylation - immunology ; Epigenetics ; Female ; Humans ; Immunosuppressive Agents - therapeutic use ; Middle Aged ; Multiple sclerosis ; Multiple Sclerosis, Relapsing-Remitting - drug therapy ; Multiple Sclerosis, Relapsing-Remitting - immunology ; Transcriptome</subject><ispartof>Journal of neuroimmunology, 2022-03, Vol.364, p.577808-577808, Article 577808</ispartof><rights>2022 The Author(s)</rights><rights>Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.</rights><rights>info:eu-repo/semantics/openAccess</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c440t-f1cccf579eddf91a015ca53279bb8bd40d8bc0c44f7d5f32c0d55346f6e06223</citedby><cites>FETCH-LOGICAL-c440t-f1cccf579eddf91a015ca53279bb8bd40d8bc0c44f7d5f32c0d55346f6e06223</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0165572822000030$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,3537,26544,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35093762$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Brorson, I.S.</creatorcontrib><creatorcontrib>Eriksson, A.M.</creatorcontrib><creatorcontrib>Høgestøl, E.</creatorcontrib><creatorcontrib>Leikfoss, I.S.</creatorcontrib><creatorcontrib>Harbo, H.F.</creatorcontrib><creatorcontrib>Berge, T.</creatorcontrib><creatorcontrib>Vitelli, V.</creatorcontrib><creatorcontrib>Bos, S.D.</creatorcontrib><title>Global DNA methylation changes in treated and untreated MS patients measured over time</title><title>Journal of neuroimmunology</title><addtitle>J Neuroimmunol</addtitle><description>Multiple sclerosis (MS) is an autoimmune, neurological disease. We investigated genome-wide DNA methylation profiles of CD4+ and CD8+ T cells from MS patients and healthy controls at baseline and a follow-up visit. Patients were all treatment-naïve at baseline, and either on treatment or remained untreated at the follow-up visit. MS patients show more changes in their T cell DNA methylation profiles as compared to healthy controls over time, with the most pronounced differences observed in the untreated MS patients. These findings underline the potential of DNA methylation as biomarkers in MS.
[Display omitted]
•Genome-wide DNA methylation profiles were obtained from MS patients and healthy controls at baseline and one follow-up visit.•MS patients were treatment-naïve at baseline, and untreated or on treatment with immunomodulatory drugs at follow-up.•MS patients show more changes in their DNA methylation profiles compared to healthy controls over time.•Untreated MS patients show more differential DNA methylation at follow-up as compared to treated MS patients .•There is an abundance of hypermethylated DMPs in CD8+ T cells from treated and untreated MS patients at the follow-up visit.</description><subject>Adult</subject><subject>CD4+ T cells</subject><subject>CD4-Positive T-Lymphocytes - immunology</subject><subject>CD8+ T cells</subject><subject>CD8-Positive T-Lymphocytes - immunology</subject><subject>Differentially methylated position</subject><subject>DNA methylation</subject><subject>DNA Methylation - immunology</subject><subject>Epigenetics</subject><subject>Female</subject><subject>Humans</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Middle Aged</subject><subject>Multiple sclerosis</subject><subject>Multiple Sclerosis, Relapsing-Remitting - drug therapy</subject><subject>Multiple Sclerosis, Relapsing-Remitting - immunology</subject><subject>Transcriptome</subject><issn>0165-5728</issn><issn>1872-8421</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>3HK</sourceid><recordid>eNqFkMtOxCAUhonR6Hh5BWXppiPQQtudxnviZaFxSyicKpMWRqAm8_ZixnHrikC-_z-HD6FjSuaUUHG2mC8cTMHbcc4IY3Ne1w1pttCMNjUrmorRbTTLIC94zZo9tB_jghDKy6rdRXslJ21ZCzZDb7eD79SAr54u8AjpYzWoZL3D-kO5d4jYOpwCqAQGK2fw5Da3xxe8zCi4FHNQxSnkR_8FASc7wiHa6dUQ4ej3PECvN9evl3fFw_Pt_eXFQ6GriqSip1rrntctGNO3VOUFteIlq9uuazpTEdN0mmS2rw3vS6aJ4fkLohdABGPlATpZ1-pgY7JOOh-UpKThTLaCsDYTp2tiGfznBDHJ0UYNw6Ac-ClKJljFCK2EyKjYlPkYA_RyGeyowioXyh_pciE30uWPdLmWnoPHvzOmbgTzF9tYzsD5GoCs4stCkFFncxqMDaCTNN7-N-Mb65SVsA</recordid><startdate>20220315</startdate><enddate>20220315</enddate><creator>Brorson, I.S.</creator><creator>Eriksson, A.M.</creator><creator>Høgestøl, E.</creator><creator>Leikfoss, I.S.</creator><creator>Harbo, H.F.</creator><creator>Berge, T.</creator><creator>Vitelli, V.</creator><creator>Bos, S.D.</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>3HK</scope></search><sort><creationdate>20220315</creationdate><title>Global DNA methylation changes in treated and untreated MS patients measured over time</title><author>Brorson, I.S. ; Eriksson, A.M. ; Høgestøl, E. ; Leikfoss, I.S. ; Harbo, H.F. ; Berge, T. ; Vitelli, V. ; Bos, S.D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c440t-f1cccf579eddf91a015ca53279bb8bd40d8bc0c44f7d5f32c0d55346f6e06223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adult</topic><topic>CD4+ T cells</topic><topic>CD4-Positive T-Lymphocytes - immunology</topic><topic>CD8+ T cells</topic><topic>CD8-Positive T-Lymphocytes - immunology</topic><topic>Differentially methylated position</topic><topic>DNA methylation</topic><topic>DNA Methylation - immunology</topic><topic>Epigenetics</topic><topic>Female</topic><topic>Humans</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Middle Aged</topic><topic>Multiple sclerosis</topic><topic>Multiple Sclerosis, Relapsing-Remitting - drug therapy</topic><topic>Multiple Sclerosis, Relapsing-Remitting - immunology</topic><topic>Transcriptome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brorson, I.S.</creatorcontrib><creatorcontrib>Eriksson, A.M.</creatorcontrib><creatorcontrib>Høgestøl, E.</creatorcontrib><creatorcontrib>Leikfoss, I.S.</creatorcontrib><creatorcontrib>Harbo, H.F.</creatorcontrib><creatorcontrib>Berge, T.</creatorcontrib><creatorcontrib>Vitelli, V.</creatorcontrib><creatorcontrib>Bos, S.D.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>NORA - Norwegian Open Research Archives</collection><jtitle>Journal of neuroimmunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brorson, I.S.</au><au>Eriksson, A.M.</au><au>Høgestøl, E.</au><au>Leikfoss, I.S.</au><au>Harbo, H.F.</au><au>Berge, T.</au><au>Vitelli, V.</au><au>Bos, S.D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Global DNA methylation changes in treated and untreated MS patients measured over time</atitle><jtitle>Journal of neuroimmunology</jtitle><addtitle>J Neuroimmunol</addtitle><date>2022-03-15</date><risdate>2022</risdate><volume>364</volume><spage>577808</spage><epage>577808</epage><pages>577808-577808</pages><artnum>577808</artnum><issn>0165-5728</issn><eissn>1872-8421</eissn><abstract>Multiple sclerosis (MS) is an autoimmune, neurological disease. We investigated genome-wide DNA methylation profiles of CD4+ and CD8+ T cells from MS patients and healthy controls at baseline and a follow-up visit. Patients were all treatment-naïve at baseline, and either on treatment or remained untreated at the follow-up visit. MS patients show more changes in their T cell DNA methylation profiles as compared to healthy controls over time, with the most pronounced differences observed in the untreated MS patients. These findings underline the potential of DNA methylation as biomarkers in MS.
[Display omitted]
•Genome-wide DNA methylation profiles were obtained from MS patients and healthy controls at baseline and one follow-up visit.•MS patients were treatment-naïve at baseline, and untreated or on treatment with immunomodulatory drugs at follow-up.•MS patients show more changes in their DNA methylation profiles compared to healthy controls over time.•Untreated MS patients show more differential DNA methylation at follow-up as compared to treated MS patients .•There is an abundance of hypermethylated DMPs in CD8+ T cells from treated and untreated MS patients at the follow-up visit.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>35093762</pmid><doi>10.1016/j.jneuroim.2022.577808</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0165-5728 |
| ispartof | Journal of neuroimmunology, 2022-03, Vol.364, p.577808-577808, Article 577808 |
| issn | 0165-5728 1872-8421 |
| language | eng |
| recordid | cdi_cristin_nora_10852_96029 |
| source | MEDLINE; NORA - Norwegian Open Research Archives; Elsevier ScienceDirect Journals |
| subjects | Adult CD4+ T cells CD4-Positive T-Lymphocytes - immunology CD8+ T cells CD8-Positive T-Lymphocytes - immunology Differentially methylated position DNA methylation DNA Methylation - immunology Epigenetics Female Humans Immunosuppressive Agents - therapeutic use Middle Aged Multiple sclerosis Multiple Sclerosis, Relapsing-Remitting - drug therapy Multiple Sclerosis, Relapsing-Remitting - immunology Transcriptome |
| title | Global DNA methylation changes in treated and untreated MS patients measured over time |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T04%3A49%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_crist&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Global%20DNA%20methylation%20changes%20in%20treated%20and%20untreated%20MS%20patients%20measured%20over%20time&rft.jtitle=Journal%20of%20neuroimmunology&rft.au=Brorson,%20I.S.&rft.date=2022-03-15&rft.volume=364&rft.spage=577808&rft.epage=577808&rft.pages=577808-577808&rft.artnum=577808&rft.issn=0165-5728&rft.eissn=1872-8421&rft_id=info:doi/10.1016/j.jneuroim.2022.577808&rft_dat=%3Cproquest_crist%3E2624201466%3C/proquest_crist%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2624201466&rft_id=info:pmid/35093762&rft_els_id=S0165572822000030&rfr_iscdi=true |